Somatostatin analogue mimics acute ischemic preconditioning in a rat model of myocardial infarction

Zong-Lun Wang, Yu H. Huang, Hang Chang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We tested the hypothesis that octreotide, a somatostatin analogue, can mimic ischemic preconditioning (PC) to provide cardioprotection against myocardial infarction. An ischemia-reperrusion model of adult Wistar rats was used. Infarct size was expressed as a percentage of the area at risk under different treatment protocols. Octreotide PC (35 μg/Kg 20 minutes before ischemia-reperfusion) significantly decreased infarct size (18 ± 4%) versus control (60 ± 7%). The somatostatin receptor antagonist cyclo-somatostatin (0.5 mg/Kg) could blunt the above cardioprotection. Administration of either chelerythrine (a protein kinase C inhibitor, 2 mg/Kg) or genistein (a tyrosine kinase inhibitor, 5 mg/Kg) could also block octreotide PC (54 ± 7% and 58 ± 6%, respectively). Pretreatment with the mitochondrial ATP-sensitive potassium channel antagonist 5-hydroxydecanoic acid (5-HD) and the sarcolemmal ATP-sensitive potassium channel antagonist glibenclamide could abolish the effects of octreotide PC (54 ± 6% and 52 ± 6%). Chelerythrine, however, had no effect on octreotide PC. In conclusion, the present study demonstrates that octreotide can mimic ischemic PC to reduce infarct size. Acute effects of octreotide PC involve the activation of protein kinase C, tyrosine kinase C, and mitochondrial ATP-sensitive potassium channels, but not systemic IGF-I activation.

Original languageEnglish
Pages (from-to)327-332
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume45
Issue number4
DOIs
Publication statusPublished - Apr 2005

Fingerprint

Ischemic Preconditioning
Octreotide
Somatostatin
Myocardial Infarction
KATP Channels
Protein-Tyrosine Kinases
Ischemia
Somatostatin Receptors
Protein C Inhibitor
Genistein
Glyburide
Protein Kinase Inhibitors
Clinical Protocols
Insulin-Like Growth Factor I
Protein Kinase C
Reperfusion
Wistar Rats

Keywords

  • Myocardial infarction
  • Receptors
  • Reperfusion
  • Signal transduction
  • Somatostatin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Somatostatin analogue mimics acute ischemic preconditioning in a rat model of myocardial infarction. / Wang, Zong-Lun; Huang, Yu H.; Chang, Hang.

In: Journal of Cardiovascular Pharmacology, Vol. 45, No. 4, 04.2005, p. 327-332.

Research output: Contribution to journalArticle

@article{7572ad295bda4ad8a347a804b39f8cbe,
title = "Somatostatin analogue mimics acute ischemic preconditioning in a rat model of myocardial infarction",
abstract = "We tested the hypothesis that octreotide, a somatostatin analogue, can mimic ischemic preconditioning (PC) to provide cardioprotection against myocardial infarction. An ischemia-reperrusion model of adult Wistar rats was used. Infarct size was expressed as a percentage of the area at risk under different treatment protocols. Octreotide PC (35 μg/Kg 20 minutes before ischemia-reperfusion) significantly decreased infarct size (18 ± 4{\%}) versus control (60 ± 7{\%}). The somatostatin receptor antagonist cyclo-somatostatin (0.5 mg/Kg) could blunt the above cardioprotection. Administration of either chelerythrine (a protein kinase C inhibitor, 2 mg/Kg) or genistein (a tyrosine kinase inhibitor, 5 mg/Kg) could also block octreotide PC (54 ± 7{\%} and 58 ± 6{\%}, respectively). Pretreatment with the mitochondrial ATP-sensitive potassium channel antagonist 5-hydroxydecanoic acid (5-HD) and the sarcolemmal ATP-sensitive potassium channel antagonist glibenclamide could abolish the effects of octreotide PC (54 ± 6{\%} and 52 ± 6{\%}). Chelerythrine, however, had no effect on octreotide PC. In conclusion, the present study demonstrates that octreotide can mimic ischemic PC to reduce infarct size. Acute effects of octreotide PC involve the activation of protein kinase C, tyrosine kinase C, and mitochondrial ATP-sensitive potassium channels, but not systemic IGF-I activation.",
keywords = "Myocardial infarction, Receptors, Reperfusion, Signal transduction, Somatostatin",
author = "Zong-Lun Wang and Huang, {Yu H.} and Hang Chang",
year = "2005",
month = "4",
doi = "10.1097/01.fjc.0000156823.35210.21",
language = "English",
volume = "45",
pages = "327--332",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Somatostatin analogue mimics acute ischemic preconditioning in a rat model of myocardial infarction

AU - Wang, Zong-Lun

AU - Huang, Yu H.

AU - Chang, Hang

PY - 2005/4

Y1 - 2005/4

N2 - We tested the hypothesis that octreotide, a somatostatin analogue, can mimic ischemic preconditioning (PC) to provide cardioprotection against myocardial infarction. An ischemia-reperrusion model of adult Wistar rats was used. Infarct size was expressed as a percentage of the area at risk under different treatment protocols. Octreotide PC (35 μg/Kg 20 minutes before ischemia-reperfusion) significantly decreased infarct size (18 ± 4%) versus control (60 ± 7%). The somatostatin receptor antagonist cyclo-somatostatin (0.5 mg/Kg) could blunt the above cardioprotection. Administration of either chelerythrine (a protein kinase C inhibitor, 2 mg/Kg) or genistein (a tyrosine kinase inhibitor, 5 mg/Kg) could also block octreotide PC (54 ± 7% and 58 ± 6%, respectively). Pretreatment with the mitochondrial ATP-sensitive potassium channel antagonist 5-hydroxydecanoic acid (5-HD) and the sarcolemmal ATP-sensitive potassium channel antagonist glibenclamide could abolish the effects of octreotide PC (54 ± 6% and 52 ± 6%). Chelerythrine, however, had no effect on octreotide PC. In conclusion, the present study demonstrates that octreotide can mimic ischemic PC to reduce infarct size. Acute effects of octreotide PC involve the activation of protein kinase C, tyrosine kinase C, and mitochondrial ATP-sensitive potassium channels, but not systemic IGF-I activation.

AB - We tested the hypothesis that octreotide, a somatostatin analogue, can mimic ischemic preconditioning (PC) to provide cardioprotection against myocardial infarction. An ischemia-reperrusion model of adult Wistar rats was used. Infarct size was expressed as a percentage of the area at risk under different treatment protocols. Octreotide PC (35 μg/Kg 20 minutes before ischemia-reperfusion) significantly decreased infarct size (18 ± 4%) versus control (60 ± 7%). The somatostatin receptor antagonist cyclo-somatostatin (0.5 mg/Kg) could blunt the above cardioprotection. Administration of either chelerythrine (a protein kinase C inhibitor, 2 mg/Kg) or genistein (a tyrosine kinase inhibitor, 5 mg/Kg) could also block octreotide PC (54 ± 7% and 58 ± 6%, respectively). Pretreatment with the mitochondrial ATP-sensitive potassium channel antagonist 5-hydroxydecanoic acid (5-HD) and the sarcolemmal ATP-sensitive potassium channel antagonist glibenclamide could abolish the effects of octreotide PC (54 ± 6% and 52 ± 6%). Chelerythrine, however, had no effect on octreotide PC. In conclusion, the present study demonstrates that octreotide can mimic ischemic PC to reduce infarct size. Acute effects of octreotide PC involve the activation of protein kinase C, tyrosine kinase C, and mitochondrial ATP-sensitive potassium channels, but not systemic IGF-I activation.

KW - Myocardial infarction

KW - Receptors

KW - Reperfusion

KW - Signal transduction

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=15744362779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15744362779&partnerID=8YFLogxK

U2 - 10.1097/01.fjc.0000156823.35210.21

DO - 10.1097/01.fjc.0000156823.35210.21

M3 - Article

VL - 45

SP - 327

EP - 332

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 4

ER -